Category: Pharmaceuticals
-
![Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer?]()
Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer?
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth a combined $5.2 billion. Merck (MRK.NASDAQ) agreed to buy ArQule (ARQL.NASDAQ) for $2.7 billion, while French drug giant Sanofi (SNY.NASDAQ) agreed to purchase Synthorx (THOR.NASDAQ) for $2.5 billion. MRK has…
-
![Cambridge House’s XFuture event spearheads brave new world of psychedelic treatments]()
Cambridge House’s XFuture event spearheads brave new world of psychedelic treatments
Last minute attendees can register for Cambridge House’s Extraordinary Future event here and use promocode: FUTURE30 for 30% off. The Extraordinary Future Conference – running September 22-23, 2019 at the Vancouver Convention Center – helps investors find profitable positions in cutting edge science and tech companies. Sneek Peak: “Zen” Ken Kuiper earns his moniker with…
-
A ‘growing’ concern: With the cannabis bubble bursting, are mushrooms the next gold rush?
“Cannabis is dead; long live cannabis.” Mushrooms, mark my words.. –Ancient potstocks proverb Seriously though, folks, the cannabis sector is in trouble. Take a look at the Horizons Marijuana Life Sciences ETF, a basket of some of the largest cannabis stocks on the market. Here is equity.guru founder, Chris Parry’s take on how the growing pains of…
-
![ProMis Neurosciences (PMN.T) and the fight against Alzheimer’s]()
ProMis Neurosciences (PMN.T) and the fight against Alzheimer’s
Someone in the world develops dementia every three seconds. Alzheimer’s disease and other dementia-related disorders affect 50M people around the world and that number is expected to double to 131.5M by 2050, that is, unless companies like ProMis Neurosciences (PMN.T) can do the unthinkable. See, our understanding of Alzheimer’s has changed dramatically since its discovery…
-
Trackloop (TOOL.C): Real business with real businesses in the logistics tracking space
To tell this story in 25 words or less would be to do it a terrible injustice, so I’ve sat on it for a bit, letting the dust settle, seeing how the market would accept it without my help. The answer to that is, meh, the market is a bit distracted right now, it’ll get…
-
X-Spray (CND.C) profits from a culture of impatience
At Equity Guru, we sometimes get news before it hits the street. Such is the case with a company called X-Sprays – which is so new it isn’t born yet. Which is to say, it only exists in its “shell form” – CNRP Mining (CND.C). Punching holes through the epidermis of the planet isn’t everyone’s…
-
Veritas Pharma (VRT.C) lays its cards on the table
When I was running the editorial show at Stockhouse, I had reason to look over a lot of messageboards for a wide variety of public companies. Almost without fail, you could bet that any given messageboard would be faced with two problems. This is how good companies end up with bad stock charts. They lose…
